PHIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Phio Pharmaceuticals Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.87−0.00 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $10.09M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -91.1% | -93.7% | -69.9% | |
| Return on assets | -73.3% | -74.0% | -63.9% | |
| Current ratio | 5.16 | 6.91 | – | |
| Debt to equity | – | 0.02 | – | |
| Net debt to EBITDA | – | 1.61× | – | |
| Capex to revenue | 21.1% | – | – | |
| Diluted shares | 0M | 0M | 6M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Phio Pharmaceuticals generated $49.83M from operations and spent $190.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$49.83M
Used
$190.00K
Capital expenditure$190.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-42419.0%
×Asset turnover0.00×
×Equity multiplier1.21×
=Return on equity, FY2019-92.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2019 | -42419.0% | 0.00× | 1.21× | -92.2% |
| FY2018 | -5333.3% | 0.01× | 1.26× | -95.5% |
| FY2017 | -83013.3% | 0.00× | 1.38× | -196.3% |
| FY2016 | -47336.8% | 0.00× | 1.24× | -91.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.70M
- Cash generatingOperating cash flow above zero-$7.98M
- Return on assets improvedROA up on the prior year-76.4% → -151.6%
- Earnings backed by cashOperating cash flow above net income-$7.98M vs -$8.70M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.65 → –
- No dilutionShare count did not rise1M → 6M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –